News | May 01, 2012

FDA Panel Recommends Approval of Cameron Health's Subcutaneous S-ICD System

May 1, 2012 — Cameron Health Inc. announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel voted 7-1 that sufficient data exists demonstrating the efficacy and safety of the S-ICD (subcutaneous-implantable cardioverter defibrillator) system for the treatment of sudden cardiac arrest (SCA).

"We are pleased with the panel's strong recommendation for approval of the S-ICD system, the world's first and only completely subcutaneous ICD for the treatment of sudden cardiac arrest," said Kevin Hykes, president and CEO of Cameron Health. "This represents another important step on the path toward FDA approval of the S-ICD system and its availability to physicians and their patients at risk for sudden cardiac arrest."

Cameron Health submitted a premarket approval application (PMA) in December 2011 based on data from a 330-patient pivotal investigational device exemption (IDE) clinical study that evaluated the safety and efficacy of the S-ICD system in patients at risk of SCA.

"The S-ICD system is a breakthrough technology that holds promise as a new alternative for treating patients at risk for sudden cardiac arrest," said Michael R. Gold, professor of medicine and chief of cardiology at the Medical University of South Carolina. "The S-ICD system provides the same defibrillation protection as conventional ICDs, but without the serious complications associated with leads that reside in the heart and blood vessels."

On March 8, 2012, Boston Scientific Corp. announced that it would exercise its option to acquire Cameron Health. Closing of the transaction is subject to customary conditions, including relevant antitrust clearance, and is expected to occur in the second or third quarter of 2012.

For more information: www.cameronhealth.com

Related Content

Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD) | September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD) | September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD) | July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD) | June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
The Unify ICD is one of the SJM devices in an FDA warning letter
Feature | Implantable Cardioverter Defibrillator (ICD) | April 14, 2017 | Dave Fornell
April 14, 2017 — The U.S. Food and Drug Administration (FDA) sent a warning letter to Abbott/St.
ICDs, non-ischemic cardiomyopathy, University of Alabama at Birmingham study, Circulation
News | Implantable Cardioverter Defibrillator (ICD) | January 18, 2017
A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-...
ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillator (ICD) | January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
Overlay Init